Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote

Nov 05 2012

• By Paul Bonanos

Related Content

Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis

Feb 12 2009

Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue

Nov 02 2012

Back To The Drawing Board For Portola After Merck Returns Betrixaban

Mar 24 2011

Freed From Merck Deal, Portola Set To Move Betrixaban Forward With $89M Funding

Nov 22 2011

Momentum Grows For Novel Oral Anticoagulants Out To Replace Warfarin

Mar 29 2010

Related Companies

Portola Pharmaceuticals, Inc.

Pfizer Inc.

Bristol Myers Squibb Company

Bayer AG

Johnson & Johnson

Boehringer Ingelheim GmbH

Merck & Co., Inc.

Novartis AG

Additional Topics

Business Strategies BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window